Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Editas Medicine Announced It Entered Into A License Agreement With Vertex Pharmaceuticals Where Vertex Will Obtain A Non-Exclusive License For Editas Medicine's Cas9 Gene Editing Technology

Author: Benzinga Newsdesk | December 13, 2023 10:06am

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel)

Agreement extends Editas Medicine's cash runway into 2026

Posted In: EDIT VRTX